drug
viloxazine hydrochloride ER
Marketedupdated 5mo agoby $SUPN SUPERNUS PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 4, 2029
~2.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Apr 2, 2035formulationUS 9662338
- Apr 2, 2035formulationUS 9662338
- Apr 2, 2035formulationUS 9662338
- Feb 7, 2033formulationUS 9358204
- Feb 7, 2033formulationUS 9358204
- Feb 7, 2033formulationUS 9358204
- Feb 7, 2033method-of-use (U-727)US 9603853
- Feb 7, 2033method-of-use (U-727)US 9603853
- Feb 7, 2033method-of-use (U-727)US 9603853
- Sep 4, 2029method-of-use (U-727)US 113247532.9y
- Sep 4, 2029method-of-use (U-727)US 113247532.9y
- Sep 4, 2029method-of-use (U-727)US 113247532.9y
- Sep 4, 2029method-of-use (U-727)US 114581432.9y
- Sep 4, 2029method-of-use (U-727)US 114581432.9y
- Sep 4, 2029method-of-use (U-727)US 114581432.9y
- Sep 4, 2029method-of-use (U-727)US 121215232.9y
- Sep 4, 2029method-of-use (U-727)US 121215232.9y
- Sep 4, 2029method-of-use (U-727)US 121215232.9y
FDA exclusivities (3)
- Apr 2, 2026NCENew Chemical Entity (5y)
- Apr 2, 2026NCENew Chemical Entity (5y)
- Apr 2, 2026NCENew Chemical Entity (5y)
News(1)
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugsSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”biospace · 2mo ago
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that